Deutscher Rheumatologiekongress 2025
Minimal disease activity – value from a patient’s view. Patient-reported outcomes in relation to MDA of oligo- and polyarticular PsA patients, a post-hoc analysis of the UPJOINT study
Text
Introduction: Upadacitinib (UPA) is an oral, reversible JAK inhibitor approved for the treatment of active PsA. Oligoarticular PsA (oPsA) typically affects ≤4 peripheral joints and can progress to polyarticular PsA (pPsA), potentially causing more joint damage [1]. This analysis aims to assess if the achievement of minimal disease activity (MDA) during UPA treatment impacts oPsA and pPsA patients-reported outcomes (PROs).
Methods: UPJOINT (NCT04758117) is a multicenter, prospective, open-label, observational study being conducted in Germany and Canada in adults (≥18 years) with PsA involving at least one swollen joint (SJC ≥1) of 66; ≥35% of the study population have oPsA. Patients of both subgroups were stratified into MDA achievers and non- achievers after 24 weeks of UPA treatment and analyzed accordingly for PROs like, pain, SF-12, DLQi and HAQ-DI (as HAQ-DI and pain is a component of MDA and no independent measure it is only shown to provide all recorded PROs).
Results: This posthoc analysis of the UpJoint study included 370 PsA patients with baseline data. Of which 38,7% were diagnosed with oPSA. A proportion of 55,8% oPSA and 32% pPsA patients achieved MDA at week 24.
Patients with MDA at week 24 in both PsA subgroups showed significant improvement from baseline in pain and health related quality of life scores, measured by SF-12 physical, SF-12 mental, HAQ-DI and DLQi, compared to patients that did not achieve MDA.
Importantly, regardless if belonging to the oPsA or pPsA subgroups, patients with MDA reported comparable scores in all measured PROs at week 24. For both patient groups the reported PRO scores were significantly improved in MDA achievers compared to the respective patient group that did not achieve MDA at week 24.
Conclusion: Regardless of the PsA subgroup of oPsA or pPsA, PRO scores were comparable within MDA achievers, highlighting the impact and value of MDA for patients’ wellbeing and quality of life.
